Contemporary medical management of systolic heart failure.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Circulation Journal

• Publication date

  2012-01-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1253/CIRCJ.CJ-11-1424PMID 22240600
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2013cited by this paper
• Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Target of Phosphodiesterase-5 Inhibition in a 1-Year Study

  2012cited by this paper
• Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial.

  2011cited by this paper
• Heart rate and heart failure. Not a simple relationship.

  2011cited by this paper
• Prognostic impact of myocardial interstitial fibrosis in non-ischemic heart failure. -Comparison between preserved and reduced ejection fraction heart failure.-.

  2011cited by this paper
• Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial

  2011cited by this paper
• Contemporary Reviews in Cardiovascular Medicine Hydralazine and Isosorbide Dinitrate in Heart Failure Historical Perspective, Mechanisms, and Future Directions

  2011cited by this paper
• Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): A Phase 2 Trial of Intracoronary Gene Therapy of Sarcoplasmic Reticulum Ca2+-ATPase in Patients With Advanced Heart Failure

  2011cited by this paper
• Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study

  2011cited by this paper
• Renal denervation and hypertension.

  2011cited by this paper
• Rationale and design of the multicentre, randomized, double‐blind, placebo‐controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT)

  2011cited by this paper
• Eplerenone in patients with systolic heart failure and mild symptoms.

  2011cited by this paper
• Anemia and iron deficiency - New therapeutic targets in heart failure?

  2010cited by this paper
• Spironolactone use and renal toxicity: population based longitudinal analysis

  2010cited by this paper
• Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial.

  2010cited by this paper
• Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.

  2010cited by this paper
• Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.

  2010cited by this paper
• Iron deficiency: an ominous sign in patients with systolic chronic heart failure.

  2010cited by this paper
• Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.

  2010cited by this paper
• Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial.

  2009cited by this paper
• Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Target of Phosphodiesterase-5 Inhibition in a 1-Year Study

  2009cited by this paper
• Anemia and iron deficiency--new therapeutic targets in heart failure?

  2009cited by this paper
• Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED‐HF): a Phase III, anaemia correction, morbidity–mortality trial

  2009cited by this paper
• Effect of the Direct Renin Inhibitor Aliskiren, the Angiotensin Receptor Blocker Losartan, or Both on Left Ventricular Mass in Patients With Hypertension and Left Ventricular Hypertrophy

  2009cited by this paper
• Ferric carboxymaltose in patients with heart failure and iron deficiency.

  2009cited by this paper
• Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A-HeFT trial.

  2009cited by this paper
• Effects of the Oral Direct Renin Inhibitor Aliskiren in Patients With Symptomatic Heart Failure

  2008cited by this paper
• Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.

  2008cited by this paper
• A GRK5 polymorphism that inhibits β-adrenergic receptor signaling is protective in heart failure

  2008cited by this paper
• Metoprolol Reverses Left Ventricular Remodeling in Patients With Asymptomatic Systolic Dysfunction: The REversal of VEntricular Remodeling with Toprol-XL (REVERT) Trial

  2007cited by this paper
• Sildenafil Improves Exercise Capacity and Quality of Life in Patients With Systolic Heart Failure and Secondary Pulmonary Hypertension

  2007cited by this paper
• Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET.

  2007cited by this paper
• Angiotensin‐converting enzyme inhibitors and survival in women and men with heart failure

  2007cited by this paper
• Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.

  2006cited by this paper
• Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.

  2005cited by this paper
• Data Supplement (unedited) at:

  2005cited by this paper
• Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.

  2004cited by this paper
• Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.

  2004cited by this paper
• Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

  2003cited by this paper
• Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

  2003cited by this paper
• Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.

  2003cited by this paper
• Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.

  2003cited by this paper
• Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials.

  2003cited by this paper
• Comparative Effects of Carvedilol and Metoprolol on Regional Vascular Responses to Adrenergic Stimuli in Normal Subjects and Patients With Chronic Heart Failure

  2003cited by this paper
• Effect of the Asp298 Variant of Endothelial Nitric Oxide Synthase on Survival for Patients With Congestive Heart Failure

  2003cited by this paper
• Eplerenone , a Selective Aldosterone Blocker , in Patients with Left Ventricular Dysfunction after Myocardial Infarction

  2003cited by this paper
• Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study.

  2003cited by this paper
• Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.

  2003cited by this paper
• Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan.

  2002cited by this paper
• Synergistic Polymorphisms of β1- and α2C-Adrenergic Receptors and the Risk of Congestive Heart Failure

  2002cited by this paper
• Effects of long-term renal sympathetic denervation on heart failure after myocardial infarction in rats

  2002cited by this paper
• Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors.

  2002cited by this paper
• Bucindolol Displays Intrinsic Sympathomimetic Activity in Human Myocardium

  2002cited by this paper
• A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

  2002cited by this paper
• Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients.

  2002cited by this paper
• Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure.

  2002cited by this paper
• Improvement in Survival and Cardiac Metabolism After Gene Transfer of Sarcoplasmic Reticulum Ca2+-ATPase in a Rat Model of Heart Failure

  2001cited by this paper
• Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.

  2001cited by this paper
• Effect of carvedilol on survival in severe chronic heart failure.

  2001cited by this paper
• A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

  2001cited by this paper
• Aldosterone Production Is Activated in Failing Ventricle in Humans

  2001cited by this paper
• Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction.

  2001cited by this paper
• A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure.

  2001cited by this paper
• Induction of cardiac fibrosis by aldosterone.

  2000cited by this paper
• Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study. High Enalapril Dose Study Group.

  2000cited by this paper
• Beta-blocker Evaluation of Survival Trial

  2000cited by this paper
• Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management.

  2000cited by this paper
• Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure: Insights From the Randomized Aldactone Evaluation Study (RALES)

  2000cited by this paper
• Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group.

  2000cited by this paper
• Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients with Heart Failure: The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)

  2000cited by this paper
• Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

  2000cited by this paper
• The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.

  1999cited by this paper
• Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group.

  1999cited by this paper
• Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I.

  1999cited by this paper
• Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

  1999cited by this paper
• Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.

  1999cited by this paper
• Beta-blockade in heart failure: a comparison of carvedilol with metoprolol.

  1999cited by this paper
• The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

  1999cited by this paper
• Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. The NETWORK Investigators.

  1998cited by this paper
• Evaluation of Intrinsic Sympathomimetic Activity of Bucindolol and Carvedilol in Rat Heart

  1998cited by this paper
• Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

  1997cited by this paper
• Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart.

  1996cited by this paper
• Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group.

  1996cited by this paper
• Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

  1996cited by this paper
• The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

  1996cited by this paper
• Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise.

  1996cited by this paper
• Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators.

  1993cited by this paper
• Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure

  1993cited by this paper
• Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group.

  1993cited by this paper
• Reduced beta 1 receptor messenger RNA abundance in the failing human heart.

  1993cited by this paper
• Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury.

  1993cited by this paper
• Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

  1992cited by this paper
• Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger.

  1992cited by this paper
• A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.

  1991cited by this paper
• Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

  1991cited by this paper
• Renal sympathetic nerves attenuate the natriuretic effects of atrial peptide.

  1989cited by this paper
• Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

  1988cited by this paper
• Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure. Results of a Veterans Administration Cooperative Study

  1987cited by this paper
• Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

  1987cited by this paper
• Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study.

  1986cited by this paper

• Minimally Invasive Ventricular Assist Device Surgery

  2020cites this paper
• Aldosterone Receptor Blockade in Heart Failure with Preserved Ejection Fraction.

  2018cites this paper
• Left Ventricular Assist Device Therapy for Destination Therapy: Is Less Invasive Surgery a Safe Alternative?

  2018cites this paper
• Histone deacetylase activity governs diastolic dysfunction through a nongenomic mechanism

  2018cites this paper
• Asistencia ventricular izquierda como terapia de destino: ¿la cirugía mínimamente invasiva es una alternativa segura?

  2018cites this paper
• Vitamin D deficiency in elderly: Risk factors and drugs impact on vitamin D status

  2018cites this paper
• Where Is the “Optimal” Fontan Hemodynamics?

  2017cites this paper
• Human Stem Cell-Derived Cardiac Model of Chronic Drug Exposure.

  2017cites this paper
• Red blood cell distribution width is a survival predictor beyond anemia and Nt-ProBNP in stable optimally medicated heart failure with reduced ejection fraction outpatients

  2016cites this paper
• Message From the Editor-in-Chief.

  2015cites this paper
• Prognostic Value of Red Blood Cell Distribution Width for Patients with Heart Failure: A Systematic Review and Meta-Analysis of Cohort Studies

  2014cites this paper
• Challenges and Opportunities in Pediatric Heart Failure and Transplantation

  2014cites this paper
• Introduction to the series: challenges and opportunities in pediatric heart failure and transplantation.

  2014cites this paper
• Role of NRSF/REST in the regulation of cardiac gene expression and function.

  2013cites this paper
• Chronic Administration of Small Nonerythropoietic Peptide Sequence of Erythropoietin Effectively Ameliorates the Progression of Postmyocardial Infarction–Dilated Cardiomyopathy

  2013cites this paper
• Exercise Intolerance in Chronic Heart Failure – Skeletal Muscle Dysfunction and Potential Therapies –

  2013cites this paper
• Molecular targets of current and prospective heart failure therapies

  2013cites this paper
• Chemotherapy and radiation regimens to breast cancer treatment induce changes in mRNA levels of renin–angiotensin system related genes in cardiac tissue

  2013cites this paper
• Titration of β-blockers for patients with heart failure.

  2013cites this paper
• Disparity of physician specialties in the management of chronic heart failure: trend analysis in Taiwan, 2000 - 2010.

  2013cites this paper
• PERIPARTUM CARDIOMYOPATHY AN OMINOUS DIAGNOSIS

  2013cites this paper
• Exercise intolerance in chronic heart failure--skeletal muscle dysfunction and potential therapies.

  2013cites this paper
• Adrenoreceptors and nitric oxide in the cardiovascular system

  2013cites this paper
• Regulation of chromatin structure in the cardiovascular system.

  2013cites this paper
• Blood pressure variability activates cardiac mineralocorticoid receptor and induces cardiac remodeling in hypertensive rats.

  2013cites this paper
• Superiority of long-acting to short-acting loop diuretics in the treatment of congestive heart failure.

  2012cites this paper